Translational research: precision medicine, personalized medicine, targeted therapies: marketing or science?
Therapie. 2015 Jan-Feb;70(1):1-19.
doi: 10.2515/therapie/2014231.
Epub 2015 Feb 16.
[Article in
English,
French]
Authors
Pierre Marquet
1
, Pierre-Henry Longeray
2
, Fabrice Barlesi
3
; participants of round table N°1 of Giens XXX:; Véronique Ameye
4
, Pascale Augé
5
, Béatrice Cazeneuve
6
, Etienne Chatelut
7
, Isabelle Diaz
8
, Marine Diviné
9
, Philippe Froguel
10
, Sylvia Goni
11
, François Gueyffier
12
, Natalie Hoog-Labouret
13
, Samia Mourah
14
, Michèle Morin-Surroca
15
, Olivier Perche
16
, Florent Perin-Dureau
17
, Martine Pigeon
18
, Anne Tisseau
2
, Céline Verstuyft
19
Affiliations
- 1 UMR 850 INSERM, CHU Limoges, Université de Limoges, Limoges, France.
- 2 Laboratoire Merck Serono SAS, Lyon, France.
- 3 Aix Marseille Université; Assistance Publique - Hôpitaux de Marseille, Service d'Oncologie Multidisciplinaire et Innovations Thérapeutiques, Marseille, France.
- 4 Laboratore Novartis Pharma SAS, Rueil Malmaison, France.
- 5 Inserm-Transfert, Paris, France.
- 6 Laboratoire Lilly France, Neuilly-sur-Seine, France.
- 7 Institut Universitaire de Cancérologie, Toulouse, France.
- 8 LEEM, Paris, France - ARIIS, Paris, France.
- 9 Laboratoire Amgen, Neuilly-sur-Seine, France.
- 10 Imperial College, London, Royaume-Uni - Institut Pasteur, Lille, France.
- 11 Laboratoire Lundbeck SASIssy-les-MoulineauxFrance.
- 12 Université Lyon 1, HCL, Lyon, France.
- 13 Institut National du Cancer, Boulogne Billancourt, France.
- 14 Assistance publique - Hôpitaux de Paris, Paris, France - Université Paris 7, Paris, France - Inserm, Paris, France.
- 15 HAS, Saint Denis la Plaine, France.
- 16 Laboratoire Roche Diagnostics, Meylan, France.
- 17 ANSM, Saint Denis, France.
- 18 CNAMTS, Paris, France.
- 19 Assistance publique - Hôpitaux de Paris, Paris, France - Faculté de Médecine Paris-Sud, Le Kremlin Bicêtre, France.
Abstract
Personalized medicine is based on: 1) improved clinical or non-clinical methods (including biomarkers) for a more discriminating and precise diagnosis of diseases; 2) targeted therapies of the choice or the best drug for each patient among those available; 3) dose adjustment methods to optimize the benefit-risk ratio of the drugs chosen; 4) biomarkers of efficacy, toxicity, treatment discontinuation, relapse, etc. Unfortunately, it is still too often a theoretical concept because of the lack of convenient diagnostic methods or treatments, particularly of drugs corresponding to each subtype of pathology, hence to each patient. Stratified medicine is a component of personalized medicine employing biomarkers and companion diagnostics to target the patients likely to present the best benefit-risk balance for a given active compound. The concept of targeted therapy, mostly used in cancer treatment, relies on the existence of a defined molecular target, involved or not in the pathological process, and/or on the existence of a biomarker able to identify the target population, which should logically be small as compared to the population presenting the disease considered. Targeted therapies and biomarkers represent important stakes for the pharmaceutical industry, in terms of market access, of return on investment and of image among the prescribers. At the same time, they probably represent only the first generation of products resulting from the combination of clinical, pathophysiological and molecular research, i.e. of translational research.
© 2015 Société Française de Pharmacologie et de Thérapeutique.
MeSH terms
-
Biomarkers
-
Clinical Trials as Topic
-
Drug Administration Schedule
-
Drug Design
-
Drug Monitoring
-
France
-
Humans
-
Marketing
-
Molecular Diagnostic Techniques
-
Molecular Targeted Therapy
-
Neoplasms / drug therapy
-
Practice Guidelines as Topic / standards
-
Precision Medicine* / trends
-
Quality Assurance, Health Care
-
Translational Research, Biomedical* / trends